American Journal of Cardiology
Volume 106, Issue 3 , Pages 316-322 , 1 August 2010

Factors Influencing Local and Systemic Levels of Plasma Myeloperoxidase in ST-Segment Elevation Acute Myocardial Infarction

  • Catriona J. Marshall, MBChB

      Affiliations

    • Cardiology Department, Christchurch Hospital, Christchurch, New Zealand
    • ,
  • Mark Nallaratnam, MBChB

      Affiliations

    • Cardiology Department, Christchurch Hospital, Christchurch, New Zealand
    • ,
  • Tessa Mocatta, BSc

      Affiliations

    • Free Radical Research Group, University of Otago, Christchurch, New Zealand
    • ,
  • David Smyth, MD

      Affiliations

    • Cardiology Department, Christchurch Hospital, Christchurch, New Zealand
    • ,
  • Mark Richards, MD, PhD

      Affiliations

    • Cardiology Department, Christchurch Hospital, Christchurch, New Zealand
    • ,
  • John M. Elliott, MBChB, PhD

      Affiliations

    • Cardiology Department, Christchurch Hospital, Christchurch, New Zealand
    • ,
  • James Blake, MBChB

      Affiliations

    • Cardiology Department, Christchurch Hospital, Christchurch, New Zealand
    • ,
  • Christine C. Winterbourn, PhD

      Affiliations

    • Free Radical Research Group, University of Otago, Christchurch, New Zealand
    • ,
  • Anthony J. Kettle, PhD

      Affiliations

    • Free Radical Research Group, University of Otago, Christchurch, New Zealand
    • ,
  • Dougal R. McClean, MD

      Affiliations

    • Cardiology Department, Christchurch Hospital, Christchurch, New Zealand
    • Corresponding Author InformationCorresponding author: Tel: 64-3-364-1122; fax: 64-3-364-1415

Received 7 December 2009 ,Revised 11 March 2010 ,Accepted 11 March 2010.

References 

  1. Baldus S, Rudolph V, Roiss M, Ito WD, Rudolph TK, Eiserich JP, et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation. 2006;113:1871–1878
  2. TIMI Study Group. The Thrombolysis In Myocardial Infarction (TIMI) trial (Phase I findings). N Engl J Med. 1985;312:932–936
  3. Mocatta TJ, Pilbrow AP, Cameron VA, Senthilmohan R, Frampton CM, Richards AM, et al. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol. 2007;49:1993–2000
  4. Böyum A. Isolation of mononuclear cells and granulocytes from human blood (Isolation of mononuclear cells by one centrifugation; and of granulocytes by combined centrifugation and sedimentation at 1 g). Scand J Clin Lab Invest. 1968;21:77–89
  5. Nauseef WM. How human neutrophils kill and degrade microbes: an integrated view. Immunol Rev. 2007;219:88–102
  6. Li G, Keenan AC, Young JC, Hall MJ, Pamuklar Z, Ohman EM, et al. Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirudin on myeloperoxidase release from neutrophils. Arterioscler Thromb Vasc Biol. 2007;27:1850–1856
  7. Naruko T, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002;106:2894–2900
  8. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med. 2002;347:5–12
  9. Dominguez-Rogriguez A, Samimi-Fard S, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC. Prognostic value of admission myeloperoxidase levels in patients with ST-segment elevation myocardial infarction and cardiogenic shock. Am J Cardiol. 2008;101:1537–1540
  10. Khan SQ, Kelly D, Quinn P, Davies JE, Ng LL. Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction. Heart. 2007;93:826–831
  11. Galijasevic S, Saed GM, Hazen SL, Abu-Soud HM. Myeloperoxidase metabolizes thiocyanate in a reaction driven by nitric oxide. Biochemistry. 2006;45:1255–1262
  12. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science. 2002;296:2391–2394
  13. Vita JA, Brennan M-L, Gokee N, Mann SA, Goormastic M, Shishebor MH, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004;110:1134–1139
  14. Baldus S, Eiserich JP, Mani A, Castro L, Figueroa M, Chumley P, et al. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest. 2001;108:1759–1770
  15. Hazen SL. Myeloperoxidase and plaque vulnerability. Arterioscler Thromb Vasc Biol. 2004;24:1143–1146
  16. Goldmann BU, Rudolph V, Rudolph TK, Holle AK, Hillebrandt M, Meinertz T, et al. Neutrophil activation precedes myocardial injury in patients with acute myocardial infarction. Free Radic Biol Med. 2009;47:79–83
  17. Griffin SV, Chapman PT, Lianos EA, Lockwood CM. The inhibition of myeloperoxidase by ceruloplasmin can be reversed by anti-myeloperoxidase antibodies. Kidney Int. 1999;55:917–925
  18. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114:529–541
  19. Aminian A, Boudjeltia KZ, Babar S, Van Antwerpen P, Lefebvre P, Crasset V, et al. Coronary stenting is associated with an acute increase in plasma myeloperoxidase in stable angina patients but not in patients with acute myocardial infarction. Eur J Intern Med. 2009;20:527–532

 Mr. Nallaratnam was supported by the New Zealand 2006 Cardiac Society/MSD Research Fellowship, Wellington, New Zealand. Ms. Mocatta was supported in part by the Health Research Council of New Zealand, Auckland, New Zealand.

PII: S0002-9149(10)00777-0

doi: 10.1016/j.amjcard.2010.03.028

American Journal of Cardiology
Volume 106, Issue 3 , Pages 316-322 , 1 August 2010

Article Tools

* Image Usage & Resolution